$9.57
-0.62[-6.08%]
At close: Apr 25
$9.57
0[0.00%]
After Hours: 5:17PM EDT
Adverum Biotechnologies
(NASDAQ:ADVM)Latest News for Adverum Biotechnologies Stock (NASDAQ:ADVM)
Adverum Biotechnologies Stock (NASDAQ: ADVM)
Categories: All
Thursday, April 25, 2024
Tuesday, April 23, 2024
Thursday, March 21, 2024
Wednesday, March 20, 2024
Tuesday, March 19, 2024
Monday, March 18, 2024
Thursday, February 08, 2024
- Why Is Blindness Focused-Adverum Biotechnologies Stock Trading Lower Today?Vandana Singh - Feb 8, 2024, 2:59PM
- Adverum Biotechnologies Announced Preliminary Safety And Efficacy Data From The Ongoing LUNA Phase 2 Trial Of Ixoberogene Soroparvovec In Patients With Wet Age-related Macular DegenerationBenzinga Newsdesk - Feb 8, 2024, 7:15AM
Tuesday, February 06, 2024
Monday, February 05, 2024
- Why Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day SessionAvi Kapoor - Feb 5, 2024, 12:56PM
- 12 Health Care Stocks Moving In Monday's Intraday SessionBenzinga Insights - Feb 5, 2024, 12:31PM
- Why Adverum Biotechnologies Stock Is Trading HigherErica Kollmann - Feb 5, 2024, 10:50AM
- Adverum Biotechnologies shares are trading higher after the company announced $127.5 million in private placement financing.Benzinga Newsdesk - Feb 5, 2024, 10:48AM
- 12 Health Care Stocks Moving In Monday's Pre-Market SessionBenzinga Insights - Feb 5, 2024, 8:06AM
- Adverum Biotechnologies Has Agreed To Sell Approximately 106.25M Shares In A Private Placement At $1.20/Share With Gross Proceeds Of Approximately $127.5M; Pro Forma Cash And Investments Expected To Fund Current Operating Plan Into Late 2025Benzinga Newsdesk - Feb 5, 2024, 7:48AM
Thursday, December 07, 2023
Thursday, November 09, 2023
Tuesday, November 07, 2023
Monday, November 06, 2023
Thursday, November 02, 2023
- Adverum Biotechnologies shares are trading higher after Mizuho initiated coverage on the stock with a Buy rating and announced a $2 price target.Benzinga Newsdesk - Nov 2, 2023, 12:57PM
- Mizuho Initiates Coverage On Adverum Biotechnologies with Buy Rating, Announces Price Target of $2Benzinga Newsdesk - Nov 2, 2023, 5:52AM
Tuesday, September 26, 2023
Tuesday, September 05, 2023
Friday, August 11, 2023
Thursday, August 10, 2023
Thursday, June 22, 2023
Wednesday, June 14, 2023
- On June 13, Adverum Biotechnologies Inc Received Written From Nasdaq Stating That Co Has Regained Compliance With Minimum Bid Price RequirementBenzinga Newsdesk - Jun 14, 2023, 4:04PM
- Adverum Biotechnologies Board Member Awarded $79K Worth of Stock OptionsBenzinga Insights - Jun 14, 2023, 11:03AM
- Adverum Biotechnologies Director Awarded $60K Worth of Stock OptionsBenzinga Insights - Jun 14, 2023, 11:02AM
- Adverum Biotechnologies Board Member Awarded $60K Worth of Stock OptionsBenzinga Insights - Jun 14, 2023, 11:01AM
Monday, June 12, 2023
Thursday, May 25, 2023
Thursday, May 18, 2023
- Adverum Biotechnologies Introduces An Intravitreal Gene Therapy Program For Geographic Atrophy And Presents Data On Its Ocular Gene Therapy PlatformHappy Mohamed - May 18, 2023, 9:10AM
- Adverum Biotechnologies Presents Nonclinical Data In Support Of Ixo-vec's Phase 2 Clinical Development At ASGCT 2023 Annual MeetingHappy Mohamed - May 18, 2023, 9:09AM